Want to join the conversation?
Pharma company $ALXN said its 3Q15 GAAP net loss was $0.81 per share, compared to diluted GAAP EPS of $0.88 in the third quarter of 2014. This was impacted by $315.6MM or $1.39 per share related to a non-cash deferred income tax expense resulting from the integration of Synageva.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.